Post
First patient enrolled in pulmonary hypertension reduction device study
Paris-based Gradient Denervation Technologies has performed the first procedure in its first-in-human clinical study for a pulmonary hypertension device. The …
Innovent and Merck to carry out cancer combination therapy trial
Innovent Biologics and Merck have entered a clinical trial collaboration and supply agreement for the combination therapy of IBI351 (GFH925) …
YS Biopharma receives approval for vaccine trial in Philippines
The Food and Drug Administration (FDA) of the Philippines has given approval to biopharmaceutical firm YS Biopharma to begin a …
Bluejay Therapeutics makes progress in Hepatitis B and D Trials
Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts …
AstraZeneca abandons inflammatory bowel disease drug
AstraZeneca’s brazikumab inflammatory bowel disease (IBD) development programme has been discontinued due to trial delays. Brazikumab, an anti-IL-23 monoclonal antibody, was …
Athersys begins enrolment in final cohort of MultiStem trial
US-based biotechnology company Athersys has begun enrolling patients in the third and final cohort of a Phase II study of …
Sirnaomics doses first patient in anticoagulant treatment trial
US-based biopharmaceutical company Sirnaomics has dosed the first patient in a Phase I clinical trial of STP122G, an RNAi drug …
Saudi astronaut concludes space experiments on inflammatory diseases
Saudi Arabia’s astronaut Rayyanah Barnawi has completed the implementation of King Faisal Specialist Hospital and Research Center (KFSH&RC) cell science …
Sensei Biotherapeutics doses patients in tumour therapy trial
US-based biotechnology company Sensei Biotherapeutics has dosed the first patient in a Phase I/II clinical trial of SNS-101 to treat …
Clearside opens enrolment in Phase IIb trial of wet AMD therapy
US-based biopharmaceutical company Clearside Biomedical has begun enrolling patients in its Phase IIb trial of CLS-AX (axitinib injectable suspension). The multi-centre …
Hookipa debuts Phase I/II data
Hookipa Pharma has reported preliminary positive data and trial updates from its ongoing phase II study of HB-200 in combination …
NeuroMetrix encouraged by Phase II Quell data
NeuroMetrix is gearing up to present partial trial results on Quell, the company’s wireless transcutaneous electric nerve stimulation (TENS) device, …
Adiso completes Phase Ib MAD study of UC therapy
Adiso Therapeutics has completed a Phase Ib multiple ascending dose (MAD) trial of ADS051 (BT051) for the treatment of moderate-to-severe …
Nacuity achieves target enrolment in RP therapy trial
Nacuity Pharmaceuticals has achieved its target enrolment of 48 patients in the SLO-RP Phase I/II clinical trial of NPI-001 tablets …
China dominates CAR-T therapies
Chimeric antigen receptor (CAR)-T cell therapy is an innovative approach within cancer treatment. By genetically modifying a patient’s own immune …